These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 3116548

  • 21. [Current aspects in the therapy of prostatic cancer].
    Urologe A; 1996 Jan; 35(1 Suppl Aktuelle):1-12. PubMed ID: 9022400
    [No Abstract] [Full Text] [Related]

  • 22. Results obtained in the treatment of prostate cancer patients with Zoladex.
    Williams G, Kerle DJ, Roe SM, Yeo T, Bloom SR.
    Prog Clin Biol Res; 1985 Jan; 185A():287-95. PubMed ID: 3162175
    [No Abstract] [Full Text] [Related]

  • 23. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H.
    Prog Clin Biol Res; 1987 Jan; 243A():401-10. PubMed ID: 3116551
    [No Abstract] [Full Text] [Related]

  • 24. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M.
    Cancer Res; 1994 Aug 01; 54(15):4091-5. PubMed ID: 8033142
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI, Walker KJ.
    Chemioterapia; 1985 Jun 01; 4(3):249-51. PubMed ID: 3161643
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
    Siegel YI, Korczak D, Lindner A.
    Eur Urol; 1991 Jun 01; 19(1):16-8. PubMed ID: 1901042
    [Abstract] [Full Text] [Related]

  • 30. Endocrine factors in the treatment of prostatic cancer.
    Pierrepoint CG, Turkes AO, Walker KJ, Harper ME, Wilson DW, Peeling WB, Griffiths K.
    Prog Clin Biol Res; 1985 Jun 01; 185A():51-72. PubMed ID: 3162177
    [No Abstract] [Full Text] [Related]

  • 31. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM.
    Clin Invest Med; 1982 Jun 01; 5(4):267-75. PubMed ID: 6819101
    [Abstract] [Full Text] [Related]

  • 32. Using Zoladex in the community.
    Trethowan C.
    Nurs Times; 1982 Jun 01; 84(9):42-3. PubMed ID: 2965341
    [No Abstract] [Full Text] [Related]

  • 33. Buserelin treatment of advanced prostatic cancer: a phase II study.
    Veronesi A, Lo Re G, Dal Bo V, Magri MD, Della Valentina M, Talamini R, Merlo A, Francini M, Monfardini S.
    Med Oncol Tumor Pharmacother; 1989 Jun 01; 6(4):255-7. PubMed ID: 2515400
    [Abstract] [Full Text] [Related]

  • 34. Reversibility of the effect of LHRH agonists and other antiandrogenic hormones on the testis: a histomorphometric study.
    Kisman OK, de Voogt HJ, Baak JA.
    Eur Urol; 1990 Jun 01; 18(4):299-301. PubMed ID: 2127019
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun 01; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct 01; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.